Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9933095 | 0.83 | SMN1; SMN2 (0.49) | ALDH1A1MAPTMAPK13CSNK1DCSNK1E | |
| SCHEMBL13481172 | 0.83 | RAB9A (0.43) | ALDH1A1MAPTKDM4EMAPK13CSNK1D | |
| SCHEMBL15885797 | 0.81 | BRAF (0.46) | ALDH1A1MAPK13CSNK1DCSNK1EMAPK12 | |
| SCHEMBL1554588 | 0.81 | CSNK1D (0.57) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL3922875 | 0.81 | L3MBTL1 (0.48) | KEAP1ALDH1A1MAPTKDM4EMAPK13 | |
| SCHEMBL28861368 | 0.81 | KEAP1 (0.50) | KEAP1ALDH1A1MAPTKDM4ENSD2 | |
| SCHEMBL2481924 | 0.80 | L3MBTL1 (0.48) | ALDH1A1MAPTKDM4ENSD2L3MBTL1 | |
| SCHEMBL4128565 | 0.79 | MAPK13 (0.54) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL4320233 | 0.79 | KEAP1 (0.37) | KEAP1ALDH1A1MAPTPDE5APDE1A | |
| SCHEMBL13874177 | 0.79 | APP (0.41) | ALDH1A1MAPTKDM4EMAPK13CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962830-B1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7605266-B2 | Azaindole inhibitors of Aurora kinases | SMITHKLINE BEECHAM (US) | 2009-10-20 | — | — | US | disclosed |
| US-7495102-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | GLAXOSMITHKLINE LLC | 2008-12-11 | — | — | US | disclosed |
| EP-1962830-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SmithKline Beecham Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7419988-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM CORP (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| WO-2007076348-A2 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-6121450-A | NON-STEROIDAL COMPOUNDS WHICH ARE HIGH AFFINITY, HIGH SELECTIVITY MODULATORS FOR STEROID RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-09-19 | — | — | US | disclosed |
| US-6093821-A | MAKING 6-(PHENYL OR HETEROARYL)-1,2-DIHYDRO-N-1-PROTECTED QUINOLINE BY REACTING THE CORRESPONDING 6-HALO-DERIVATIVE WITH AN ORGANOBORATE AND ACID TREATMENT TO FORM THE 6-BORO-DERIVATIVE, COUPLING WITH PHENYL OR HETEROARYL HALIDE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-07-25 | — | — | US | disclosed |
| US-5994544-A | PRODUCING A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-11-30 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | KEAP1 1205/4885ALDH1A1 1793/4885MAPT 2145/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | KEAP1 1205/4885ALDH1A1 1793/4885MAPT 2145/4885 |
| US-20080306120-A1 | Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides | AURKA, AURKC, AURKB | KEAP1 710/4885ALDH1A1 1043/4885MAPT 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.